PMID- 23834040
OWN - NLM
STAT- MEDLINE
DCOM- 20140630
LR  - 20130709
IS  - 1699-5198 (Electronic)
IS  - 0212-1611 (Linking)
VI  - 28 Suppl 2
DP  - 2013 Mar
TI  - Current medical treatment of diabetes type 2 and long term morbidity: how to 
      balance efficacy and safety?
PG  - 3-13
LID - 10.3305/nh.2013.28.sup2.6707 [doi]
AB  - Current medical treatment of type 2 diabetes mellitus (T2DM) requires special 
      attention to different comorbidities that often are associated with 
      hyperglycemia, such as overweight or obesity, dyslipidemia, hypertension, 
      microvascular or macrovascular complications, etc. .. The control of these 
      factors risk to health is as important as the glucose control in diabetes type 2, 
      it is essential for the antidiabetes drugs consider these risk factors. The 
      consensus statement published by the ADA/EASD and AACE emphasizes that the 
      potential effects of antidiabetes medications on CV risk factors besides 
      hyperglycemia (ie, overweight/obesity, hypertension, and dyslipidemia) should be 
      considered in pharmacotherapy selection. Since T2DM is a progressive disease with 
      worsening HbA1C values over time, monotherapy, even with different agents, will 
      eventually fail to maintain the glycemic target. Because insulin resistance 
      occurs in a variety of organs and tissues, many patients may achieve fasting 
      glycemic control but develop postprandial hyperglycemia. Other issues include the 
      risk for hypoglycaemia or weight gain with traditional glucose-lowering 
      medications. The AACE/ACE algorithm for glycemic control is structured according 
      to categories of HbA1C and suggests an HbA1C goal of =6.5%, although that may not 
      be appropriate for all patients.42 The algorithm recommends monotherapy, dual 
      therapy, or triple therapy based on initial HbA1C level of 6.5% to 7.5%, 7.6% to 
      9%, and >9% and reserves initiation of insulin therapy until treatment with oral 
      or other injectable agents has failed. GLP-1 receptor agonists and DPP-4 
      inhibitors are novel options to improve glycemic control and reduce the incidence 
      of weight gain. Combination therapy with newer and traditional agents improves 
      glycemic control with a low incidence of hypoglycemia.
CI  - Copyright (c) AULA MEDICA EDICIONES 2013. Published by AULA MEDICA. All rights 
      reserved.
FAU - Carrera Boada, C A
AU  - Carrera Boada CA
AD  - Department of Endocrinology, Hospital de Clinicas, Av. Panteon, Urb. San 
      Bernardino, Caracas, Venezuela. carrera.car@gmail.com
FAU - Martinez-Moreno, J M
AU  - Martinez-Moreno JM
LA  - eng
PT  - Journal Article
PL  - Spain
TA  - Nutr Hosp
JT  - Nutricion hospitalaria
JID - 9100365
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Algorithms
MH  - Blood Glucose/analysis
MH  - Diabetes Mellitus, Type 2/blood/complications/*drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/therapeutic use
EDAT- 2013/08/31 06:00
MHDA- 2014/07/01 06:00
CRDT- 2013/07/10 06:00
PHST- 2013/07/10 06:00 [entrez]
PHST- 2013/08/31 06:00 [pubmed]
PHST- 2014/07/01 06:00 [medline]
AID - 10.3305/nh.2013.28.sup2.6707 [doi]
PST - ppublish
SO  - Nutr Hosp. 2013 Mar;28 Suppl 2:3-13. doi: 10.3305/nh.2013.28.sup2.6707.